CDR-Life Inc. has reported preclinical data for the CDR-813, a novel antibody fragment-based bivalent T-cell engager targeting preferentially expressed antigen in melanoma (PRAME) on HLA-A*02:01.

Pharmaceutical companies are making investments in research of therapies that target three different antigen-binding sites.

Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape ...

An example of targeted therapy is antibody-drug conjugates (ADCs), which are designed to deliver a cancer-killing ...

Antibodies are proteins that play a crucial role in the immune response by recognizing and binding to specific antigens ... The incorporation of non-natural amino acids, such as pH-sensitive ...

A team of researchers has discovered an antibody that can counter all known variants of the COVID-19 virus. The scientists also claim the antibody can also resist distantly related viruses that ...

Bispecific antibodies connect the immune system with cancer cells. They offer an efficacious treatment option, but there are side effects. Bispecific antibodies are promising treatments for patients ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...

The other heavy chain of the vaguely Y-shaped antibody targets CD38, another myeloma target. Binding to all three targets brings the T cell and the tumor together, Konto said. From there ...

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | ...